Oveporexton for Narcolepsy: Effectiveness and Value

Draft Questions for Deliberation and Voting: May 14, 2026 Public Meeting

These questions are intended for the deliberation of the Midwest CEPAC voting body at the public meeting.

Patient Population for all questions: *Adults with Narcolepsy type 1*

Special Ethical Priorities

To help inform judgments of overall long-term value for money, please answer the following questions:

1=Typical obligations, 2=Some added obligations, 3=Substantial added obligations

1. Are there particular obligations to people with this condition because of disease severity and/or unmet need with currently available therapies?

2. Are there particular obligations to people with this condition because it disproportionately affects those from a racial/ethnic group that have not been equitably served by the healthcare system?

3. Apart from issues around disease severity/unmet need and race/ethnicity, are there other particular obligations to people with this condition?

Clinical Evidence

4. For adults with narcolepsy type 1, is the current evidence adequate to demonstrate that the net health benefit of oveporexton is greater than that of no pharmacological treatment?

   Yes No

5. For adults with narcolepsy type 1, is the current evidence adequate to demonstrate that the net health benefit of oveporexton is greater than that of modafinil with venlafaxine?

   Yes No

6. For adults with narcolepsy type 1, is the current evidence adequate to demonstrate that the net health benefit of oveporexton is greater than that of sodium oxybate?

   Yes No

7. For adults with narcolepsy type 1, is the current evidence adequate to demonstrate that the net health benefit of oveporexton is greater than that of pitolisant?

   Yes No

Benefits Beyond Health

To help inform judgments of overall long-term value for money, please answer the following questions about oveporexton when compared to sodium oxybates, modafinil plus venlafaxine, pitolisant and no pharmacological treatment:

1=No, 2=Yes: small improvement, 3=Yes: substantial improvement

8. Is oveporexton likely to improve caregivers' quality of life and/or ability to pursue their own education, work, and family life?

9. If payment/cost were not an issue, would oveporexton be likely to improve access to treatment because of its method of delivery and/or treatment setting?

10. Other: as determined pre-meeting by ICER team based on input from patients, clinical experts, and appraisal committee members

Long-Term Value for Money

11. Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering benefits beyond health and special ethical priorities, what is the long-term value for money of oveporexton at assumed pricing?*
    a. High long-term value for money at assumed pricing
    b. Intermediate long-term value for money at assumed pricing
    c. Low long-term value for money at assumed pricing

**This vote will only be taken if a price becomes available for oveporexton.*